A shadow market for unlicensed weight-loss medications is being driven by social media fitness personalities and vendors on communication apps, according to new investigations.
Investigational Treatment Acquiring Popularity Via Social Media
Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its supposed fat-burning effects. Followers are urged to message these accounts directly for source information, while also obtaining discount codes.
Thriving Commerce on Messaging Platforms
Separately, a flourishing market exists on Telegram, where communities with numerous of members share comparison images, injection guides and assertions of next-day British shipping. Sellers promote the drug there before directing customers to WhatsApp for transactions.
Understanding Retatrutide
Retatrutide is an investigational injectable developed by US drugmaker Eli Lilly. The drug targets three gut hormones – GLP-1, GIP and glucagon. Preliminary studies indicate it could help individuals reduce up to 25% of their body weight. Nicknamed the “triple G”, the substance is being hailed online as the successor to Ozempic.
Medical Professionals Voice Worries
Nevertheless, doctors and pharmacists have warned that the sale of what is still an unlicensed medication in the UK is a cause for concern and could lead to individuals administering substances of uncertain source.
Several professionals stated the demand for the experimental drug could be connected to the increasing cost of licensed slimming products such as Mounjaro.
Legal Position and Enforcement
Marketing the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unlicensed drug that cannot be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.
Some influencers try to circumvent the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but promotion and distribution can still violate medicines, advertising, and consumer regulations, potentially leading to penalties, legal action or imprisonment.
Platform Reaction and Content Elimination
According to TikTok, the platform has removed violative material and banned related keywords and search suggestions. The company said it was dedicated to keeping the platform safe and investing in strengthening enforcement strategies.
Online Trading Operations
Investigations also found communities with up to nine thousand members selling retatrutide using the platform's integrated search feature, which functions like a public directory. Typing “retatrutide” immediately brings up channels with numerous of members, populated with photos of weight loss, positive testimonials and step-by-step instructions for mixing or injecting at residence.
After moments of entering one group, a seller posted WhatsApp details, where the majority of purchases occur. The seller provided an guidebook and guaranteed shipping within two days. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a image of a supposed testing documentation. Not one asked about body mass, health issues or previous experience.
Product Information and Pricing
Inside these communities, posts display dark colored parcels with postal service labels, stating to contain new batches. One communication stated: “It took eight of us to load them this morning.”
Buyers can choose between powder vials, mixed at home with purified liquid, or ready-to-use injectors typically sold at 160 pounds for 20mg. When questioned how much time a injector should last, sellers give contradictory answers ranging from a few weeks to “depends on your body”.
Platform Oversight and Safety Actions
A spokesperson for the messaging service said it actively monitored dangerous material on its service including content that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Warnings
“Individuals are administering substances they can’t verify. Even if the science behind retatrutide is valid, these digital versions may not contain what they claim,” said a pharmacy expert, the director of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to recent price rises for approved weight-loss drugs such as Mounjaro. “With costs rising, patients are using online platforms. But counterfeit treatments are highly risky. You can’t be certain what’s contained or whether the environment they were made in was clean,” she said.
Her team has already seen patients injured by self-injection from unconfirmed suppliers. “We understand the disappointment, but purchasing from messaging apps or communication platforms is gambling with your health,” said the doctor. “These substances could be contaminated or improperly measured.”
Manufacturer Position
A spokesperson from Eli Lilly said the substance was in phase 3 research studies and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for personal consumption,” they said, noting that any product “misleadingly claiming itself as a company experimental product not yet approved … may subject users to possibly significant health risks”.
